Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up.
Saved in:
| Title: | Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up. |
|---|---|
| Authors: | Papp KA; Alliance Clinical Research and Probity Medical Research, Waterloo. Electronic address: kapapp@probitymedical.com., Blauvelt A; Oregon Medical Research Center, Portland., Puig L; Department of Dermatology, IIB Sant Pau, Hospital de la Santa Creu i Sant Pau, Barcelona., Ohtsuki M; Department of Dermatology, Jichi Medical University, Tochigi., Beissert S; Department of Dermatology, University Hospital Carl Gustav Carus, TU Dresden, Dresden., Gooderham M; SKiN Centre for Dermatology, Probity Medical Research, and Department of Medicine, Queen's University, Ontario., Amin AZ; Northwestern Medicine Dermatology, Chicago., Liu J; AbbVie Inc., North Chicago., Wu T; AbbVie Inc., North Chicago., Azam T; AbbVie Inc., North Chicago., Stakias V; AbbVie Inc., North Chicago., Espaillat R; AbbVie Inc., North Chicago., Sinvhal R; AbbVie Inc., North Chicago., Soliman AM; AbbVie Inc., North Chicago., Pang Y; AbbVie Inc., North Chicago., Chen MM; AbbVie Inc., North Chicago., Lebwohl MG; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York. |
| Source: | Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2023 Dec; Vol. 89 (6), pp. 1149-1158. Date of Electronic Publication: 2023 Aug 06. |
| Publication Type: | Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Mosby Country of Publication: United States NLM ID: 7907132 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-6787 (Electronic) Linking ISSN: 01909622 NLM ISO Abbreviation: J Am Acad Dermatol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
